Deutsche Bank analyst Emmanuel Papadakis upgraded Roche (RHHBY) to Hold from Sell with a price target of CHF 265, up from CHF 235. The firm is less cautious on the shares following fenebrutinib’s results in multiple sclerosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY: